Supplementary Figures include the survival curves of the significant MR genes which did not present the same profile curve on GSE21501, GSE28735 and MEXP2780 arrays. The selection of MRs followed these criteria: (a) they should be verified in all three arrays and also (b) they should present the same profile curve (e.g., if low gene expression was associated with greater chances of survival in one array, the same feature should be observed in the next arrays); if not, the data were considered conflicting and were then discarded. Survival curves were estimated by Kaplan-Meier method. LogRank test was used to compare the survival and Hazard Ratios with 95% confidence intervals were calculated.



Supplementary Figure S1. Kaplan-Meier curve of *ZNF407*. GSE21501 was the only array which presented significant diference between low-high *ZNF407* expression (*p*-value=0.01634). HR have indicated 1.85 greater chances of survival for patients who had low *ZNF407* expression.



Supplementary Figure S2. Kaplan-Meier curve of *MYSM1*. Low-high *MYSM1* expression comparison was significant diferent on the GSE21501 array, with *p*-value=0.01866. Patients with high *MYSM1* expression had 0.34 greater chances of survival.

ZZZ3



Supplementary Figure S3. Kaplan-Meier curve of *ZZZ3*. GSE21501 and GSE28935 were the only arrays which presented significant diference between low-high *ZZZ3* expression (*p*-value=0.00253 and *p*-value=0.02784, respectively). HR have indicated 0.32 greater chances of survival for patients who had high *ZZZ3* expression in GSE21501, whereas patients with low *ZZZ3* expression had 2.95 greater chances of survival in GSE28735. Both survival curves were significant, however, the data were discordant.

ZFP91



Supplementary Figure S4. Kaplan-Meier curve of *ZFP91*. Low-high *ZFP91* expression comparison was significant diferent on the GSE21501 and GSE28735 arrays, with *p*-value=0.01655 and *p*-value=0.0462, respectively. Patients with low *ZFP91* expression had 1.83 greater chances of survival in GSE21501, whereas HR have indicated 0.31 greater chances of survival for patients who had high *ZFP91* expression in GSE28735. Both survival curves were significant, however, the data were discordant.



Supplementary Figure S5. Kaplan-Meier curve of *ZNF41*. Low-high *ZNF41* expression comparison was significant diferent on the GSE21501 array, with *p*-value=0.01857. Patients with low *ZNF41* expression had 1.9 greater chances of survival.



Supplementary Figure S6. Kaplan-Meier curve of *HSF4*. GSE21501 and GSE28935 were the only arrays which presented significant diference between low-high *HSF4* expression (*p*-value=0.00654 and *p*-value=0.04136, respectively). Patients with low *HSF4* expression had 2.08 greater chances of survival in GSE21501, whereas HR have indicated 0.31 greater chances of survival for patients who had high *HSF4* expression in GSE28735. Both survival curves were significant, however, the data were discordant.

ARID4B



Supplementary Figure S7. Kaplan-Meier curve of *ARID4B*. GSE21501 and GSE28935 were the only arrays which presented significant diference between low-high *ARID4B* expression (*p*-value=0.00571 and *p*-value=0.0251, respectively). HR have indicated 0.33 greater chances of survival for patients who had high *ARID4B* expression in GSE21501, whereas patients with low *ARID4B* expression had 2.71 greater chances of survival in GSE28735. Both survival curves were significant, however, the data were discordant.



Supplementary Figure S8. Kaplan-Meier curve of *PRDM10*. GSE21501 and MEXP2780 were the only arrays which presented significant diference between low-high *PRDM10* expression (*p*-value=0.00032 and *p*-value=0.01617, respectively). Patients with high *PRDM10* expression had 0.275 and 0.25 greater chances of survival in GSE21501 and MEXP2780, respectively. Although the curves were significant on two arrays, the third array did not present significance, thus we could not include *PRDM10* as a possible pancreatic cancer biomarker in this work. However more studies are necessary to demonstrate the role of *PRDM10* on pancreatic cancer.

SMARCE1

GSE21501



GSE28735



MEXP2780



Supplementary Figure S9. Kaplan-Meier curve of *SMARCE1*. Low-high *SMARCE1* expression comparison was significant diferent on the GSE21501, GSE28935 and MEXP2780 arrays, with *p*-value=0.00153, *p*-value=0.00757 and *p*-value=0.00669, respectively. HR have indicated 0.275 greater chances of survival for patients who had high *SMARCE1* expression in GSE21501, whereas in GSE28735 and MEXP2780 arrays, patients with low *SMARCE1* expression had 3.15 and 3.13 greater chances of survival, respectively. In this case, we could not assume any data, despite all curves were significant, since data were conflicting.



Supplementary Figure S10. Kaplan-Meier curve of *ZNF3*. Low-high *ZNF3* expression comparison was significant diferent on the GSE21501 and MEXP2780 arrays, with *p*-value=0.03884 and *p*-value=0.00158, respectively. Patients with low *ZNF3* expression had 0.42 greater chances of survival in GSE21501, whereas HR have indicated 0.21 greater chances of survival for patients who had high *ZNF3* expression in MEXP2870. Both survival curves were significant, however, the data were discordant.

ZNF280D

GSE21501



GSE28735



MEXP2780



Supplementary Figure S11. Kaplan-Meier curve of *ZNF280D*. Low-high *ZNF280D* expression comparison was significant diferent on the GSE21501, GSE28935 and MEXP2780 arrays, with *p*-value=0.0033, *p*-value=0.01128 and *p*-value=0.00121, respectively. HR have indicated 0.32 greater chances of survival for patients who had high *ZNF280D* expression in GSE21501, whereas in GSE28735 and MEXP2780 arrays, patients with low *ZNF280D* expression had 2.76 and 3.88 greater chances of survival, respectively. In this case, we could not assume any data, since data were conflicting.



Supplementary Figure S12. Kaplan-Meier curve of *NFE2L2*. GSE21501 was the only array which presented significant diference between low-high *NFE2L2* expression (*p*-value=0.00551). HR have indicated 0.33 greater chances of survival for patients who had high *NFE2L2* expression.